Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carrilizumab plus concurrent chemoradiotherapy in locally advanced head and neck squamous cell carcinoma
ChiCTR2100041824Phase 4Recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of camrelizumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Anhui Provincial Tumor Hospital. Primary endpoints: Objective response rate (ORR), Disease control rate (DCR) and 3 more. Started Dec 2020; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2100041824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041824.